Your browser doesn't support javascript.
loading
A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma.
Zeng, Xianghua; Jia, Yingxin; Chen, Hongmei; Luo, Qinli; Zhao, Huakan; Liang, Guanzhong; Chen, Wen; Li, Yongsheng.
Afiliação
  • Zeng X; Department of Medical Oncology, Chongqing University Cancer Hospital and Chongqing Cancer Institute, Chongqing, 400030, China.
  • Jia Y; Department of Medical Oncology, Deyang Hospital of Traditional Chinese Medicine, Deyang, 618000, China.
  • Chen H; Department of Medical Oncology, Chongqing Ba'nan Hospital of Traditional Chinese Medicine, Chongqing, 400055, China.
  • Luo Q; Health Examination and Oncology Screening Center, Chongqing University Cancer Hospital and Chongqing Cancer Institute, Chongqing, 400030, China.
  • Zhao H; Department of Medical Oncology, Chongqing University Cancer Hospital and Chongqing Cancer Institute, Chongqing, 400030, China.
  • Liang G; Department of Medical Oncology, Chongqing University Cancer Hospital and Chongqing Cancer Institute, Chongqing, 400030, China.
  • Chen W; Department of Medical Oncology, Chongqing University Cancer Hospital and Chongqing Cancer Institute, Chongqing, 400030, China. 836049985@qq.com.
  • Li Y; Department of Medical Oncology, Chongqing University Cancer Hospital and Chongqing Cancer Institute, Chongqing, 400030, China. lys@cqu.edu.cn.
J Cancer Res Clin Oncol ; 149(11): 9213-9219, 2023 Sep.
Article em En | MEDLINE | ID: mdl-37188985
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Medicamentos Biossimilares / Neoplasias Hepáticas Tipo de estudo: Health_economic_evaluation Limite: Humans Idioma: En Revista: J Cancer Res Clin Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Medicamentos Biossimilares / Neoplasias Hepáticas Tipo de estudo: Health_economic_evaluation Limite: Humans Idioma: En Revista: J Cancer Res Clin Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China